Sugi Predict

Sugi Predict / Compounds / SCHEMBL9965600

SCHEMBL9965600

SCHEMBL9965600

Cc1cccc(NC(c2cccc(C(F)(F)F)c2)c2ccc3cccnc3c2O)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MDM2 Q00987 8/20 1.00
▸ MAPT P10636 6/20 0.74
▸ SMN1; SMN2 Q16637 3/20 0.74
▸ TP53 P04637 3/20 0.74
▸ P4HB P07237 4/20 0.64
▸ KDM4E B2RXH2 3/20 0.64
▸ ALDH1A1 P00352 3/20 0.64
▸ HTT P42858 2/20 0.64
▸ L3MBTL1 Q9Y468 2/20 0.64
▸ TDP1 Q9NUW8 2/20 0.64
▸ LMNA P02545 2/20 0.63
▸ MEN1 O00255 1/20 0.63
▸ HSP90AA1 P07900 1/20 0.63
▸ KMT2A Q03164 1/20 0.63
▸ GAA P10253 1/20 0.59
▸ JMJD7 P0C870 1/20 0.57
▸ CYP2D6 P10635 1/20 0.57
▸ CYP2C9 P11712 1/20 0.57
▸ CYP2C19 P33261 1/20 0.57
▸ HIF1A Q16665 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1700899 0.90 MDM2 (1.00) MDM2MAPTSMN1; SMN2TP53P4HB
SCHEMBL21351568 0.88 MDM2 (0.78) MDM2MAPTSMN1; SMN2TP53P4HB
SCHEMBL14961226 0.87 MAPT (0.81) MDM2MAPTSMN1; SMN2TP53P4HB
SCHEMBL18131752 0.87 MAPT (0.81) MDM2MAPTSMN1; SMN2TP53P4HB
SCHEMBL18131664 0.87 MAPT (0.81) MDM2MAPTSMN1; SMN2TP53P4HB
SCHEMBL1701293 0.87 MAPT (0.81) MDM2MAPTSMN1; SMN2TP53P4HB
SCHEMBL15781937 0.87 MDM2 (0.77) MDM2MAPTSMN1; SMN2TP53P4HB
SCHEMBL18197735 0.86 TP53 (0.79) MDM2MAPTSMN1; SMN2TP53P4HB
SCHEMBL9965696 0.85 MDM2 (0.75) MDM2MAPTSMN1; SMN2TP53P4HB
SCHEMBL15783135 0.85 MAPT (1.00) MDM2MAPTSMN1; SMN2TP53P4HB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566849-B1 8-HYDROXY-QUINOLINE DERIVATIVES AVIDIN KUTATO FEJLESZTOE ES KERESKEDELMI KORLATOLT FELELOESSEGUE TARSASAG (HU) 2019-09-18 — — EP disclosed
US-9273031-B2 Combination therapy with MDM2 and EFGR inhibitors Errico, Joseph P. (US) 2016-03-01 — — US disclosed
US-9238641-B2 — — 2016-01-19 — — US disclosed
US-9073858-B2 Methods of targeted drug development Errico, Joseph P. (US) 2015-07-07 — — US disclosed
US-9073858-B2 Methods of targeted drug development Errico, Joseph P. (US) 2015-07-07 — — US disclosed
US-9023354-B2 Combination therapy with MDM2 and EFGR inhibitors Errico, Joseph P. (US) 2015-05-05 — — US disclosed
US-20150105412-A1 COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS ERRICO, JOSEPH P. 2015-04-16 — — US disclosed
US-8871937-B2 8-hydroxy-quinoline derivatives “AVIDIN” Kutato, Fejleszto es Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2014-10-28 — — US disclosed
US-20140194439-A1 METHODS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-07-10 — — US disclosed
US-20140194439-A1 METHODS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-07-10 — — US disclosed
US-20140163069-A1 COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-12 — — US disclosed
US-20140163069-A1 COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-12 — — US disclosed
US-20140134163-A1 COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS Errico, Joseph P. (US) 2014-05-15 — — US disclosed
US-8658170-B2 Combination therapy with MDM2 and EFGR inhibitors Errico, Joseph P. (US) 2014-02-25 — — US disclosed
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) 2013-05-23 — — US disclosed
US-20120156197-A1 COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS Errico, Joseph P. (US) 2012-06-21 — — US disclosed
US-20110301193-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2011-12-08 — — US disclosed
US-20110301193-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2011-12-08 — — US disclosed
WO-2011148208-A1 8-HYDROXY-QUINOLINE DERIVATIVES "AVIDIN" KUTATÓ, FEJLESZTŐ ÉS KERESKEDELMI KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG (HU) 2011-12-01 — — WO disclosed
WO-2011085126-A2 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT ERRICO JOSEPH P 2011-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120156197-A1 COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS TP53, EGFR, MDM2 MDM2 3/4885MAPT 3015/4885SMN1; SMN2 907/4885
US-20110301193-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 MDM2 448/4885MAPT 1076/4885SMN1; SMN2 3999/4885
US-20140163069-A1 COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 MDM2 354/4885MAPT 1268/4885SMN1; SMN2 3974/4885
US-20150105412-A1 COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS TP53, EGFR, MDM2 MDM2 3/4885MAPT 3015/4885SMN1; SMN2 907/4885
US-20140134163-A1 COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS TP53, EGFR, MDM2 MDM2 3/4885MAPT 3015/4885SMN1; SMN2 907/4885
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES CYP2C8, NQO1, KEAP1 MDM2 2015/4885MAPT 2319/4885SMN1; SMN2 1845/4885
US-20140194439-A1 METHODS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB4 MDM2 288/4885MAPT 1499/4885SMN1; SMN2 4080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.